| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082177 | Drug Discovery Today: Disease Models | 2008 | 9 Pages |
Abstract
Pre-clinical drug discovery persistently requires novel non-human primate (NHP) models for a quicker and more ethical compound profiling. Delayed type hypersensitivity (DTH) is a low invasive and non-terminal model based on the induction of local cellular immune responses. This review compiles the most common options or possible readouts for this model to become a relevant tool for pre-clinical compound testing in the immunology field.
Section editors:Margreet Jonker, Michel Vierboom and Bert 't Hart – Biomedical Primate Research Centre BPRC, Rijswijk, The Netherlands
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Francisco Córdoba, Grazyna Wieczorek, Ellen Preussing, Marc Bigaud,